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Abstract
Current gene therapy technology is limited by the
paucity of methodology for determining the location
and magnitude of therapeutic transgene expression in
vivo. We describe and validate a paradigm for monitor-
ing therapeutic transgene expression by noninvasive
imaging of the herpes simplex virus type 1 thymidine
( )kinase HSV-1-tk marker gene expression. To test pro-
portional coexpression of therapeutic and marker
genes, a model fusion gene comprising green fluores-
( )cent protein gfp and HSV-1-tk genes was generated
( )tkgfp gene and assessed for the functional coexpres-
sion of the gene product, TKGFP fusion protein, in rat
9L gliosarcoma, RG2 glioma, and W256 carcinoma cells.
Analysis of the TKGFP protein demonstrated that it can
serve as a therapeutic gene by rendering tkgfp trans-
duced cells sensitive to ganciclovir or as a screening
marker useful for identifying transduced cells by fluo-
rescence microscopy or fluorescence-activated cell
( )sorting FACS . TK and GFP activities in the TKGFP
fusion protein were similar to corresponding wild-type
proteins and accumulation of the HSV-1-tk–specific ra-
diolabeled substrate, 2X-fluoro-2X-deoxy-1b-D-arabino-
( )furanosyl-5-iodo-uracil FIAU , in stability transduced
clones correlated with gfp-fluorescence intensity over a
wide range of expression levels. The tkgfp fusion gene
itself may be useful in developing novel cancer gene
therapy approaches. Valuable information about the ef-
ficiency of gene transfer and expression could be ob-
tained by non-invasive imaging of tkgfp expression
(with FIAU and clinical imaging devices gamma camera,
[ ]positron-emission tomography PET , single photon
[ ])emission computed tomography SPECT , and/or di-
rect visualization of gfp expression in situ by fluores-
cence microscopy or endoscopy.
Keywords: thymidine kinase, ganciclovir, FIAU, cancer gene therapy, fusion genes,
imaging.
Introduction
Experimental and clinical cancer gene therapy strategies
were first developed by using transduction of the thymidine
( )kinase gene of the herpes simplex virus type 1 HSV-1-tk
[ ]into proliferating tumor cells 1–5 . Further approaches for
gene therapy of cancer have used genes encoding other
[ ]prodrug activating enzymes, such as cytochrome P450 6 ;
[ ]cell-cycle regulating proteins, such as p53 and pRB 7 ;
[ ] [ ]inhibitors of angiogenesis 8 ; or cytokines 9 to enhance
the immune response to tumor antigens or have taken
advantage of the selective oncolysis mediated by mutant
[ ] [ ]herpes or adenoviruses 10–19 20,21 . Successful gene
therapy of tumors in a clinical setting appears to be limited
by insufficient and nonspecific gene delivery. Noninvasive
imaging technologies that provide information about the
localization, magnitude, and duration of therapeutic trans-
gene expression in vivo would greatly facilitate assessment
and implementation of novel gene therapy vectors with
better gene delivery and expression characteristics.
Currently, several approaches are being developed to
establish clinically applicable noninvasive imaging technolo-
[ ]gies of transgene expression 22–29 . These imaging tech-
nologies are based on the detection of marker enzyme–
mediated accumulation of specific radiolabeled marker sub-
[ ]strates 22–25 , binding and accumulation of marker recep-
[ ]tor–specific compounds 26–28 , or binding and accumula-
[ ]tion of gene-specific oligonucleotides 29 with gamma cam-
( )era, positron emission tomography PET , and magnetic
( )resonance imaging MRI .
The vast majority of therapeutic genes, however, do not
have appropriate marker substrates that can be radiola-
beled or would accumulate in transduced tissues to a level
that could be detected by noninvasive imaging. Therefore, it
is necessary to develop indirect imaging strategies for moni-
toring the expression of different therapeutic genes. This
can be achieved by functional coexpression of marker and
therapeutic genes. The most important requirement of this
approach is a proportional and constant coexpression of the
( )marker gene HSV-1-tk or gfp and ‘‘therapeutic’’ gene over
the wide range of expression levels. Proportionality of coex-
pression may be achieved by using an internal ribosome
( ) [ ]entry site IRES element of picornaviruses 30 to link the
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two genes in an expression cassette under control of a
[ ]single promoter 31–35 . A more direct approach, is to
produce a fusion gene that would encode for a ‘‘marker/
[ ]therapeutic’’ fusion protein 36,37 .
In this report, we describe a paradigm for monitoring the
expression of therapeutic transgenes that retain functional
activity when coexpressed as a fusion protein. This can be
achieved when both the therapeutic and marker subunits of
the fusion protein retain functional activity. In this context,
we constructed a tkgfp fusion gene and assessed the
( )proportionality of HSV-1 thymidine kinase TK and green
( )fluorescent protein GFP activity over the wide range of
expression levels in transduced cells in culture.
Materials and Methods
Cell Culture
[ ]Rat 9L gliosarcoma cells 38 were grown as monolayers
(in Dulbecco’s modified Eagle medium DMEM; Mediatech,
)Washington, DC supplemented with 10% fetal bovine serum
( )FBS; Sigma, St. Louis, MO and 100 U/mL penicillin and
( )100 mg/mL streptomycin P/S; Sigma . The RG2 and W256
cell lines were grown in MEM supplemented with 10% FBS
and antibiotics. All cells were grown at 378C in a 5% Carbon
dioxide/95% air atmosphere.
Cloning of the tkgfp Fusion Gene
The cDNA encoding the thymidine kinase gene of HSV-1
[ ]was obtained by digestion of pLTKRNL 2 with BamHI. To
facilitate further cloning, the 2.2-kb fragment encoding the
open reading frame of the HSV-1-tk was isolated and lig-
( )ated into plasmid, pcDNA3.1/Zeo Invitrogen , after diges-
( )tion with BamHI. The resulting plasmid pTKZeo3.2; 7.8 kb
was sequentially digested with BamHI and XmaI. BamHI
( )cuts 57 base pairs bp in front of the start codon of tk and
XmaI cuts 22 bp in front of the STOP codon. The resulting
Figure 1. Structure and elements of TK and GFP expressing plasmids
(pTKGFP, pHSV-TK HSV-1 amplicon plasmid as positive control for TK
) (function and pHSV-GFP HSV-1 amplicon plasmid as positive control
)for GFP function . All genes of interest, tkgfp, native HSV-1-tk, and
native gfp, respectively, are cloned under control of the CMV immediate
( )early 1 promoter pCMV . Further structural elements comprise a
( )neomycin resistance gene neoR under control of an SV40 promoter.
( )Controls contain also the HSV-1 origin of DNA replication oriS and the
( )HSV-1 DNA cleavage/packaging signal pac , which would allow pack-
aging of these amplicon plamids into HSV-1 virions.
Figure 2. Construction of the SFG -TKGFP retroviral vector. The vector
( ) ( )MoT A was used to produce the SFG -TKGFP vector B from pTKGFP
( )see Figure 1 .
1.2-kb tk fragment was isolated and ligated to the 4.7-kb
(DNA fragment obtained after plasmid pEGFP-N1 Invitro-
)gen was digested sequentially with BglII and XmaI. After
ligation, the open reading frames of both tk and gfp are
( )in-frame within the pTKGFP expression plasmid 5.9 kb ,
placing the tkgfp cDNA under control of the cytomegalo-
( ) ( ) ( )virus CMV immediate early IE 1 promoter Figure 1 .
Cloning of the tkgfp Fusion Gene into a Retroviral Vector
A retroviral vector encoding the fusion protein TKGFP
was constructed in the Moloney murine leukemia virus–
[ ]based SFG vector backbone 39 , as previously described
[ ]40 . pTKGFP was digested with Not I, then treated with
Klenow to blunt the fragment, and then digested with Mlu I.
( )The vector MoT Figure 2A , which encodes HSV-1-tk alone
[ ]41 , was digested with BamHI, blunted with Klenow, and
then digested with Mlu I. The construct was named as
( )SFG-TKGFP Figure 2B . Ten micrograms of plasmid DNA
was transfected by calcium phosphate coprecipitation as
[ ]previously described 40 into the GPG29 packaging cell
[ ]line 42 . VSV-G–pseudotyped particles were used as cell
[ ]free viral stocks 43 to transduce tumor cell lines.
Retroviral Transduction of Tumor Cell Lines
The rat RG2 glioma and rat W256 carcinoma cells were
exposed to the medium containing SFG-TKGFP retrovirus
( 6 ) ( );10 /mL in presence of polybrene 8 mg/mL for 8
hours. GFP-positive transduced RG2TKGFPq and
W256TKGFPq cells were detected by fluorescence mi-
croscopy. Single-cell–derived clones were obtained from a
mixed population of transduced RG2TKGFPq and W256
TKGFPq cells by seeding the cells into the 96 well plates
at a density of 0.1 cell /well. GFP-positive RG2TKGFPq
and W256 TKGFPq colonies were identified by fluores-
cence microscopy and used for further propagation into
single-cell–derived clonal populations.
Functional Assessment of pTKGFP
The initial functional assessment of the tkgfp gene con-
struct included the determination of green fluorescence and
( )ganciclovir GCV -sensitivity in transiently transfected rat 9L
gliosarcoma cells in culture. For both evaluations, 80%
( )confluent monolayers of 9L cells 600,000/35mm dish were
transfected with the plasmid pTKGFP or control plasmids
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( )pHSV-TK and pHSV-GFP see the next section or no
( )vector with lipofectamine GIBCO BRL , according to the
(manufacturer’s protocol 1mg DNA q6 ml lipofectamine per
)35-mm dish . For fluorescent detection of gfp-expressing
cells, culture plates were examined with a standard fluores-
(cence microscope Zeiss IM35; Carl Zeiss Inc, Thornwood,
)NY 24 hours after transfection. For determination of the
ganciclovir sensitivity, GCV-treatment was carried out at
final concentrations of 0, 0.1, 0.3, 1, 3 and 9 mg/mL medium
for half of the dishes starting 24 hours after transfection.
Four days later, surviving 9L cells were determined as a
percentage of non –GCV-treated transfected cells. A
( )tk-bearing HSV-1 amplicon plasmid pHSV-TK, 11.8 kb
featuring the tk gene under control of the CMV IE1 pro-
( )moter Figure 1 and an HSV-1 amplicon plasmid containing
(gfp under control of the CMV IE1 promoter pHSV-GFP;
)10.4 kb; Figure 1 served as positive controls. All experi-
ments were performed in triplicate and repeated 3 times.
Functional Assessment of GFP Expression in Transduced
Clones
The expression of GFP in retrovirally transduced
single-cell derived clones of RG2TKGFPq and W256
TKGFPq cells was assessed by fluorescence-activated cell
( )sorting FACS analysis of GFP fluorescence on a FAC-
( )Sstar Plus analyzer Becton Dickinson, NJ . Cells were
detached by trypsinization, counted suspended in phos-
( ) 6phate-buffered solution PBS at 48C at a density of 10
cells/mL. GFP fluorescence was measured at the wave
( )length of 488 nm. Parental nontransduced RG2 and W256
Figure 3. GFP expression in proliferating rat 9L gliosarcoma cells transfected with pTKGFP or pHSV-GFP. Comparable intensities of gfp fluorescence
( )were identified in 9L cells 24 hours after transfection for both the pTKGFP expression plasmid and the pHSV-GFP amplicon plasmid positive control .
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cells were used as negative controls. Gates were designed
to include viable single cells only. The range of fluorescence
was set to include no more than 1% of corresponding
control cells. The mean GFP fluorescence per cell was used
as a measure of GFP expression in a clonal population of
transduced cells.
Functional Assessment of HSV-1-TK Expression in Trans-
duced Clones
The single-cell–derived clones of RG2TKGFPq and
W256 TKGFPq cells were seeded in 150=25-mm culture
( )dishes at 5000 cells per dish and grown until 50% conflu-
ent. The incubation medium was replaced with 14 mL of
[14 ] ( ) ( )medium containing 2- C -FIAU fialuridine 56 mCi/mmol
[3 ] ( ) (and methyl- H -TdR 65.4 mCi/mmol Moravek Biochemi-
)cals, Brea, CA . Radiochemical purity of each compound
was checked in our laboratory by high performance liquid
( )chromatography HPLC and found to be more than 97%
[14 ] [3 ]pure. The concentrations of 2- C -FIAU and methyl- H -
( )TdR thymidine deoxyribose were 0.01 and 0.1 mCi/mL,
respectively. The cells were harvested by using a scraper
(after various periods of incubation 10, 30, 60, 90, and 120
)minutes , weighed, and assayed with a Packard B1600
TriCarb b-spectrometer and standard 3H and 14C
dual-channel counting techniques. The medium was counted
before and after incubation. The data were expressed as a
( )harvested cell-to-medium concentration ratio dpm/g cells /
( ) [ ]dpm/mL medium and plotted against time 22 . The
steady-state accumulation rate of FIAU, normalized by that
of TdR, was obtained from the slopes of the plot and used
(as a measure of HSV-1-tk gene expression in culture FIAU
)/TdR ratio .
Western Blot Analysis
The expression of TK and GFP were evaluated by West-
ern blotting with a rabbit polyclonal HSV-TK antiserum and
( )a rabbit anti-GFP antibody CLONTECH, Palo Alto, CA .
Twenty-four hours after transfection of 4 mg each of purified
( )pTKGFP, pHSV-TK positive control for TK , or pHSV-GFP
( )positive control for GFP into 9L cells, monolayers were
harvested and resuspended in phosphate buffered saline
( ) [ ]1=PBS and processed as described previously 44 . In
brief, after cell lysis, samples were boiled for 5 minutes and
electrophoresed on denaturing 10% acrylamide gels
overnight. Proteins were transferred to a Hybond-ECL mem-
( )brane Amersham, Arlington Hts., IL by standard tank
( )transfer in Tris-glycine transfer buffer at 45 V 0.5 mA for 3
hours. Nonspecific membrane binding was blocked by incu-
bating the membrane in 10% nonfat dry milk in PBS-Tween
( )overnight. After washing 3= , the membrane was incu-
(bated with primary antibodies anti-TK 1:1000 and anti-GFP
)1:1000, respectively, in 1% nonfat dry milk/PBS-Tween for
( )1 hour at room temperature. After washing 3= , the mem-
brane was incubated with horseradish peroxidase –
( )conjugated horse antirabbit 1:4000 immunoglobulin in
blocking solution for 1 hour, then washed, and developed by
( )using the ECL reagents Amersham .
Statistical Analyses
The mean values"SD of cell counts and the percent
differences between GCV-treated and nontreated dishes
were calculated and results plotted with the software pack-
age SigmaPlot 1.02. The analysis of coexpression of
HSV-1-tk and gfp genes was done with StatView 4.57
( ) (Abacus Concepts, CA and Kaleidagraph 3.08 Synergy
)Software, CA .
Results
The tkgfp Fusion Gene was Cloned in Frame Under Control
of CMV IE1 or Retroviral LTR Promoters
The expression plasmid pTKGFP bears the HSV-1-tk
gene in-frame to the gfp gene under control of the CMVIE
( ) ( )promoter Figure 1 . Twenty-two base pairs bp are missing
at the 3X end of the open reading frame of tk to remove the
stop codon. Eighteen base pair in-frame encoding
Pro-Gly-Ser-Ile-Ala-Thr were introduced between the open
reading frames for tk and gfp. HSV-1 amplicon plasmids,
which feature the tk gene or the gfp gene alone under the
( )same CMV promoter CMV IE1; Figure 1 served as posi-
tive controls for subsequent experiments. In the retroviral
vector, SFG-TKGFP, the tkgfp fusion gene is under control
X ( )of the 5 -retroviral LTR promoter Figure 2 .
The Levels of gfp-Expression are Comparable in Cells
Transduced with tkgfp and Native gfp Genes
In order to compare the levels of gfp-expression, plas-
mids pTKGFP and pHSV-GFP were transfected into rat 9L
gliosarcoma cells. The levels of gfp-expression were as-
sessed 1, 2, 3, and 5 days after transfection with a standard
fluorescence microscope and were visually of similar inten-
Figure 4. Ganciclovir dose - dependent killing of proliferating rat 9L
(gliosarcoma cells in culture. 9L cells 600,000 per 35-mm well; DAY
)zero were transfected with 1 mg DNA of each pTKGFP, pHSV -TK
( ) ( )positive control , pHSV-GFP, or no plasmid negative control by using
(6 m l lipofectamine. One day after transfection, GCV 0, 0.1, 0.3, 1, 3,
)and 9 mg/mL medium was added to culture plates. Four days later
surviving cells were trypsinized and counted. Bars represent mean
values and SD from triplicate experiment.
Neoplasia v Vol. 1, No. 2, June 1999
TKGFP Fusion Gene Imaging Jacobs et al.158
Figure 5. FACS analysis of gfp gene expression in single cells– derived
( ) ( )clones of RG2GFPTKq C and W256GFPTKq D cells. Parental
( ) ( )RG2 cells A and W256 cells B were used as controls.
( )sity in tkgfp and native gfp transfected cells Figure 3 . The
data indicate that tkgfp transduced cells can be readily
identified by fluorescent light at least to the same extent as
gfp transduced cells. As was pointed out by Loimas et al.
[ ]36 , the intracellular expression pattern of the TKGFP
seems different than the native GFP. TKGFP is mostly
concentrated in the nucleus, whereas the native GFP dis-
plays a predominantly cytoplasmic distribution.
GCV-Sensitivity is Similar in pTKGFP and pHSV-TK Trans-
fected 9L Cells
In order to investigate the ability of the TKGFP fusion
protein to mediate significant sensitivity towards the pro-drug
ganciclovir, pTKGFP and pHSV-TK transduced 9L glioma
( )cells positive control were treated with different amounts of
GCV ranging from 0 to 9 mg/mL over a 5-day exposure
period. After the treatment period, surviving cells were de-
termined as a percentage of non–GCV-treated controls. In
contrast to pHSV-GFP and nontransfected negative con-
trols, the pTKGFP and pHSV-TK transfected 9L cells were
both sensitive to GCV in a similar dose-dependent manner
( )Figure 4 .
Coexpression of gfp and HSV-1-tk Genes
To investigate the spectrum of transgene coexpression
that is achieved in polyclonal cell populations, we generated
two series of clones to examine coexpression of both genes
in the context of fusion gene expression. We obtained
multiple retrovirally transduced RG2TKGFPq and
W256TKGFPq clones with different levels of transgene
(expression due to different genomic sites of retroviral inte-
)gration to explore coexpression over a broad range of
transgene expression levels. The proportionality of the
HSV-1-tk and gfp gene expression was assessed in culture
by using the radiotracer and FACS assays, respectively. For
FACS analysis of GFP, the range of fluorescence was set to
include no more than 1% of corresponding control cells
( )Figure 5 . The mean GFP fluorescence per cell was used
as a measure of GFP expression in a clonal population of
transduced cells. Regression analysis demonstrated a
strong relationship between the levels of expression of gfp
and HSV-1-tk genes in corresponding clones of retrovirally
( )transduced RG2 glioma cells RG2TKGFPq ; Figure 6A
( )and in W256 carcinoma cells W256TKGFPq ; Figure 6B .
Combining the RG2TKGFPq and W256TKGFPq data sets
yields a similar relationship over a wide range of transgene
( )expression levels Figure 6C . Statistical analysis of the
combined data also revealed that there was a significant
(correlation between the HSV-1-tk and gfp expression rs
0.894; P- .0001; and ts2.477; P- .05 based on paired
)t-test analysis . This suggests that the relationship of fusion
gene–mediated coexpression is independent of tissue type.
The TKGFP Protein is Recognized by Both Anti-TK and
Anti-GFP Antibodies
In order to investigate the tkgfp fusion gene expression
at the protein level, cellular proteins of pTKGFP, pHSV-GFP,
( )Figure 6. Fusion-gene-mediated coexpression of the HSV-1-tk and gfp genes in culture. Gfp gene expression mean GFP fluorscence /cell was
( ) ( )assessed by FACS analysis in RG2STLEO A and W256STLEO B transduced single cell clones and plotted against measurements of the HSV-1-tk
( )gene expression FIAU/TdR accumulation ratio . The relationship between the two measurements was defined by regression analysis. The same
( )relationship was observed when the RG2STLEO and W256STLEO data sets were combined C .
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Figure 7. Western blot analysis of the TKGFP fusion protein. 4 mg of
plasmid DNA of each, pTKGFP, pHSV-GFP, and pHSV-TK, respec-
tively, were transfected into 9L cells. Monolayers were harvested 24
hours after transfection, resuspended, lysed, boiled, and proteins elec-
trophoresed over night. After protein transfer and blocking of unspecific
(binding, the membrane was incubated with primary antibodies 18;
)anti -TK 1:1000 and anti-GFP 1:1000 and, after washing, with
( )horseradish peroxidase–conjugated horse anti - rabbit 1:4000 immuno-
globulin, then washed and developed. As indicated, the primary anti-TK
( )antibody recognizes TK at approximately 46 kD third lane from left ,
and the primary GFP antibody recognizes the GFP at approximately 27
( )kD fifth lane from left . Both antibodies recognize the TKGFP fusion
( )protein at greater than 66 kD first and fourth lane from left .
and pHSV-TK–transfected 9L cells harvested at 24 hour
after transfection were resolved by SDS-PAGE and ana-
lyzed on Western blots by using antibodies to TK and GFP
( )Figure 7 . The predominant band recognized by both the
TK and the GFP antibodies is 66 kD, the appropriate size of
the TKGFP fusion protein. TK and GFP proteins are, as
expected, recognized only by their specific antibodies and
(maintain their native size approximately 46 kD and 27 kD,
)respectively .
Discussion
The paradigm for noninvasive imaging of therapeutic gene
expression that we propose in this report relies on propor-
tional coexpression of a ‘‘marker’’ gene and a ‘‘therapeutic’’
gene products. Usually, the coexpression of two gene prod-
ucts is achieved by using a dual-promoter approach. How-
ever, on an individual cell level, as opposed to cell popula-
tions in which total expression is averaged, proportional
coexpression may be compromised because of promoter
interference or transcriptional repression. The proportional-
ity of IRES-mediated coexpression of two genes is deter-
mined at the translational level and depends on protein
synthetic activity and cell cycle phase of the transduced
[ ] ( )cells 45 . Strictly proportional equimolar coexpression of
two genes under control of a single promoter can be
achieved by using fusion gene approach.
To assess whether the fusion gene approach is applica-
ble to the described imaging paradigm, we constructed the
tkgfp fusion gene consisting of the HSV-1-tk marker gene
( )for noninvasibe imaging and the gfp gene, which served
as model gene for different therapeutic transgenes. Trans-
duction of different types of tumor cells with tkgfp allowed
the selection of transduced living cells by fluorescence
microscopy and quantitation of tkgfp expression with FACS
analysis. Expression of tkgfp induced sensitivity of the
transduced tumor cells to GCV similar to that resulting from
transduction of the cells with the same vector bearing the
HSV-1-tk gene alone. The levels of HSV-1-tk gene expres-
sion in tkgfp- transduced clones, as measured by the FIAU
accumulation, were comparable to those observed by us
previoulsy in RG2 and W256 tumor cells transduced with
[ ]HSV1-1-tk gene alone 22,23 and were within the range
that is adequate for noninvasive imaging with radioiodinated
FIAU and gamma camera, single photon emission com-
( ) [ ]puted tomography SPECT , or PET 22–24 . Previously,
we have shown that the FIAU/TdR accumulation ratio corre-
lates highly with other independent measures of the
HSV-1-tk gene expression: namely, ganciclovir sensitivity
( ) [ ]IC and concentration of HSV-1-tk mRNA 22 .50
Most importantly, we demonstrated that fusion gene ap-
proach provides a constant relationship between the ex-
pression of the HSV-1-tk and gfp genes over a wide range
of expression levels. Thus, noninvasive images of HSV-1-tk
expression should reflect distribution and level of expres-
sion of gfp or different therapeutic genes. Parametric im-
ages of therapeutic gene expression could be generated if
the relationship between the levels of FIAU accumulation
( )HSV-1-tk expression and functional measures of thera-
peutic gene expression in transduced tissues are known.
Limitations of the fusion gene–fusion protein approach is
that is cannot be applied to proteins that may loose function-
ality as the result of fusion or will not be able to localize to
the appropriate subcellular compartment. This approach
(cannot be applied to secretory proteins e.g., cytokines,
)growth factors because the HSV-1-tk marker enzyme
should remain intracellular in order to catalyze the intra-
cellular accumulation of radiolabeled FIAU. Potentially higher
immunogenicity of fusion proteins may also limit their appli-
cation in in vivo studies.
The tkgfp fusion gene can also be considered as thera-
peutic-marker gene construct, where tk is used as thera-
peutic gene and gfp as marker gene for in situ detection or
direct visualization. GFP is the most widely used marker
protein for direct visualization of transgene expression in
living cells and transparent tissues and organisms in vivo
[ ] [ ]46–54 . Recently, Flotte et al. 53 implemented a videoen-
doscopy technique for direct visualization of gfp-transduced
airway epithelium. Similar endoscopic technique for visual-
ization of tkgfp fusion gene expression could be useful for
gene therapy directed to the gastrointestinal tract by using
the HSV-1-tk /GCV paradigm. Therefore, tkgfp fusion gene
could be used as a dual-marker gene for noninvasive imag-
ing, direct endoscopic visualization, and in situ detection
with fluorescence microscopy.
From a vector design prospective, the tkgfp fusion gene
has several positive features. A relatively small coding re-
( ) ( )gion of tk 1.2 kb and gfp 750 bp results in a tkgfp fusion
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gene that is less than 2 kb in size and allows for easy
incorporation into virus vectors with small transgene capaci-
( )ties e.g., adeno-associated virus vector . The transgene
capacity of adeno-associated virus vectors is less than 5 kb,
(which makes cloning of two transgenes therapeutic and
)selection gene within the same vector difficult. The
GFP-fluorescence is not dependent on substrates or cofac-
tors, which enables direct detection of transgene expression
in living cells. Therefore, the need for time-consuming im-
munocytochemistry and histochemistry for the detection of
transduced cells can be avoided. This is particularly impor-
tant because of the lack of a readily available antibody for
HSV-1-tk. Furthermore, GFP-expressing cells can be rapidly
isolated from a pool of transduced cells by FACS. This
avoids time-consuming drug selection and allows for frac-
tionation of cells with respect to the level of GFP expression
and, in turn, the level of tk expression.
Summary
The proportionality of coexpression of two genes in fusion,
the HSV-1-tk and gfp, was demonstrated over the wide
range of expression levels. Fusion gene approach should
be applicable to the paradigm of monitoring therapeutic
transgene expression by noninvasive imaging of marker
gene coexpression. Noninvasive imaging of transgene ex-
pression should facilitate assessment of the efficacy and
target specificity of novel gene delivery vectors by defining
the distribution, level, and temporal profile of expression of
different therapeutic genes in vivo. It would contribute signif-
icantly to further development of vector technology and
gene therapy in general.
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